巴瑞替尼治疗重度斑秃的104周长期疗效与安全性:BRAVE-AA1和BRAVE-AA2研究结果
该研究整合BRAVE-AA1和BRAVE-AA2两项III期试验数据,评估巴瑞替尼2mg或4mg持续治疗重度斑秃(SALT≥50)至104周的疗效与安全性。结果显示,第52周应答者中90.7%(4mg)和89.2%(2mg)维持SALT≤20,混合应答者中39.1%达到SALT≤20,未发现新安全信号。
要点
- 巴瑞替尼4mg和2mg组第52周应答者至104周维持SALT≤20的比例分别为90.7%和89.2%。
- 第52周混合应答者中39.1%在104周达到SALT≤20,提示部分患者需长期治疗才能获益。
- 最常见治疗中出现的不良事件包括COVID-19、上呼吸道感染、头痛等,未观察到新安全信号。
核心结论
- 巴瑞替尼在重度斑秃患者中104周内维持高水平的疗效,部分患者长期治疗可进一步改善。
研究设计与样本
- 整合BRAVE-AA1和BRAVE-AA2两项III期试验数据,纳入SALT评分≥50的成人重度斑秃患者,随机接受巴瑞替尼2mg或4mg持续治疗至104周。
主要发现
- 4mg组第52周应答者(N=129)中90.7%维持SALT≤20至104周,2mg组(N=65)为89.2%。
- 第52周混合应答者(N=110)中39.1%在104周达到SALT≤20。
- 各组的眉毛和睫毛再生持续改善。
关键数值与推荐
- 第52周应答者定义为SALT评分≤20;混合应答者定义为第52周SALT>20但既往访视曾达SALT≤20和/或眉毛或睫毛较基线显著改善。
- 主要结局为第104周达到SALT≤20(头皮脱发≤20%)的患者比例。
临床怎么用
- 对于巴瑞替尼治疗第52周达到SALT≤20的重度斑秃患者,继续治疗至104周可维持高应答率。
- 部分第52周未达SALT≤20但眉毛或睫毛有改善的患者,延长治疗至104周仍可能获益。
局限性
- 数据在治疗中断后删失,可能影响长期结局的完整评估。
- 研究仅纳入完成52周治疗并符合持续治疗条件的患者,存在选择偏倚可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Efficacy of the Janus kinase (JAK) inhibitor baricitinib for severe alopecia areata (AA) continuously increased over 52 weeks in two Phase 3 trials. There are limited long-term data on JAK inhibitors in AA. OBJECTIVES: To evaluate efficacy and safety of baricitinib for severe AA through 104 weeks of continuous therapy. METHODS: Integrated data from the BRAVE-AA1 and BRAVE-AA2 Phase 3 trials included adults with Severity of Alopecia Tool (SALT) scores ≥50 (≥50% scalp hair loss) randomized to and continuously treated with 2-mg or 4-mg baricitinib through Week 104. Patients who qualified to remain on continuous treatment included subjects who achieved SALT score ≤20 at Week 52 (Week-52 responders; 2-mg: N = 65; 4-mg: N = 129) and baricitinib 4-mg-treated patients who had SALT score >20 at Week 52 but achieved SALT score ≤20 at prior visit(s) and/or had significant improvement in eyebrow or eyelash hair growth relative to baseline by Week 52 (Week-52 mixed responders; N = 110). Week-104 outcomes included the proportion of patients achieving SALT score ≤20 (≤20% scalp hair loss). Data were censored after treatment discontinuation. RESULTS: Among baricitinib 4-mg-treated and baricitinib 2-mg-treated Week-52 responders, 90.7% and 89.2%, respectively, maintained SALT score ≤20 at Week 104. Among Week-52 mixed responders, 39.1% reached SALT score ≤20 by Week 104. Continued improvement in eyebrow and eyelash regrowth was observed across groups. The most frequent treatment-emergent adverse events were COVID-19, upper respiratory tract infection, headache, nasopharyngitis, acne, urinary tract infection and creatine phosphokinase increase. CONCLUSIONS: Baricitinib demonstrated a high level of maintenance of efficacy over 104 weeks in patients with severe AA. Efficacy increased in Week-52 mixed responders, illustrating that long-term treatment is necessary to observe maximum benefit in some patients. No new safety signals were observed.
引用
- Senna M, Mostaghimi A, Ohyama M, et al. Long-term efficacy and safety of baricitinib in patients with severe alopecia areata: 104-week results from BRAVE-AA1 and BRAVE-AA2. J Eur Acad Dermatol Venereol. 2024. PMID: 38391212. doi:10.1111/jdv.19665
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。